Watch for NDA/MAA submissions for deucrictibant XR prophylaxis; the company already has an NDA/MAA under review for the on-demand IR formulation. Regulatory decisions and potential commercial launch timeline are the next catalysts.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this press release- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $33.83entry
- T+1 · 4d ago −1.39%α −1.03% · $33.36
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rate by 83% vs placebo (p<0.0001) across all HAE types, with 45% of patients attack-free over 24 weeks. The drug was generally well tolerated with no treatment-related serious adverse events. This is a late-stage biotech with a $2.4B market cap, and the data supports its potential as an oral prophylactic therapy for HAE.
Key Facts
- Phase 3 CHAPTER-3 met primary and all secondary efficacy endpoints with statistical significance
- Deucrictibant XR reduced monthly HAE attack rate by 83% vs placebo across all HAE types (p<0.0001)
- In HAE Type 1 or 2, attack rate reduced by 87% vs placebo
- 45% of deucrictibant-treated participants were attack-free over the entire 24-week treatment period
- 98%, 96% and 65% achieved at least 50%, 70% and 90% reductions in attack rate vs pre-treatment
- No treatment-related serious adverse events, no treatment-related cardiovascular adverse events reported
- Deucrictibant has orphan drug designation from FDA, European Commission, and Swissmedic
- Phase 2 OLE showed 92.4% average reduction in attack rate over up to ~34 months
Financial Impact
Positive Phase 3 data for a late-stage biotech's primary asset; market cap $2.4B; deucrictibant is the only pipeline drug
Risk Factors
- Regulatory approval is not guaranteed; FDA may require additional data or raise concerns
- Competition from existing injectable prophylactics and emerging oral therapies
- Commercial execution risk as a late-stage biotech transitioning to commercial stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401883 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Viewing Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers